Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Recent studies have reported an association between serum high-density lipoprotein cholesterol (HDL-C) levels and the progression of kidney dysfunction. However, findings from studies including patients with chronic kidney disease (CKD) have been inconsistent. This study aimed to investigate the association between serum HDL-C levels and kidney function decline in patients with CKD.
We retrospectively analyzed the data obtained from a single-center prospective cohort (UMIN000041335). The association between baseline serum HDL-C levels and the composite kidney outcome, defined as kidney failure requiring replacement therapy (KFRT) or a ≥40% decline in estimated glomerular filtration rate (eGFR) from baseline, was evaluated using Cox proportional hazards models. Longitudinal changes in eGFR were analyzed using mixed-effects models. Patients were categorized into four groups according to serum HDL-C levels: <40, 40–59, 60–79, and ≥80 mg/dL.
The median (interquartile range) eGFR at baseline was 46.3 (26.5–65.9) mL/min/1.73 m². Among 946 patients, 181 patients experienced a composite kidney outcome during a median follow-up period of 29.0 months. When the HDL-C level of 60–79 mg/dL was used as the reference category, the adjusted hazard ratios (95% confidence intervals) for HDL-C levels of <40, 40–59, and ≥80 mg/dL were 1.52 (0.84–2.75), 1.18 (0.79–1.76), and 2.26 (1.39–3.68), respectively. Restricted cubic spline analysis revealed a U-shaped association between serum HDL-C levels and the risk of composite kidney outcomes. In the mixed-effects model, a trend toward a faster decline in eGFR was observed in patients with HDL-C ≥80 mg/dL compared with those with the other HDL-C levels, with a significant overall difference among the four categories (P = 0.049).
In this study, higher HDL-C levels were significantly associated with CKD progression, whereas lower HDL-C levels showed a non-significant trend toward increased risk. These findings suggest that both extremes of HDL-C may reflect underlying pathophysiological conditions contributing to kidney disease progression.
